Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
The last two posts on this blog detail how - for all practical purposes - UCB (the large Belgian pharmaceutical company) has lost the patent to one of its main drugs (Vimpat) and not told the market. See here and here. EBIT is likely to fall 30-40 percent eventually. The company might dain one day to fill shareholders in on the details. The numbers are really not pretty but without proper company disclosure it is impossible to make an accurate estimate. For almost two weeks I have expected the UCB to make a statement. But they have kept silent failing to disclose key information to the market.The patent's death certificate was only sent by the United States Patent and Trademark office last Monday and there are different time-zones and languages to deal with. So I drafted the blog-posts gently, expecting a confirming press release along with accurate statement of prognosis from the company.The patents death certificate is however almost certainly final. This is a clear statement of fact by the Patent Office against the patent. Appeals against patents are almost always on matters of law - and courts are reluctant to overturn fact-finders. All previous actions against this patent have been on law. A finding of fact against UCB is devastating. This is not ordinary course of business patent litigation. In the ordinary course of business UCB has wound up in patent disputes with other companies (eg Mylan, Argentum). And those disputes have been where the assumption is that UCB has a valid patent.This time it is in dispute with the US Government. And the US Government is stating there is no valid patent. Ask other European companies how disputes with the US Government pan out.Moreover the burden of proof has changed. UCB now has to get its patent approved under de-novo standards when the Patent Office has already rejected the patent. Of course none of this seems to warrant any statement from UCB.Lower standardsI am going to be blunt. Withholding a piece of information this significant from the market in the US would result in a fairly nasty SEC inquiry complete with subpoenas to determine who knew what and when. I have made relatively few investments in Belgium so I can't tell whether the Belgian regulatory standards are lower or the standards are just lower at UCB.But standards are very low here.In the US if a single insider has sold whilst in possession of this information (which was unreleased to the market) they could expect close investigation by Preet Bharara. I don't know what standards apply in Belgium.As stated in previous postsI found the IR officers we met of very high integrity. But this has to extend higher than this. I think it has to rise to the level of Jean-Christophe Tellier - the well regarded CEO.The Jean-Christophe Tellier was described in the press release announcing his appointment as playing "a key role in driving the growth of UCB’s three core medicines, Cimzia®, Vimpat® and Neupro®."Presumably he knows that his strategy surrounding those drugs is dead. Presumably he is part of withholding that information from the market.In the US his days as CEO would be numbered.I can only presume that standards are lower in Belgium. But if UCB claims to have high standards Mr Tellier should be fired.John
This is a follow up to last Friday's post about UCB - the large Belgian pharmaceuticals company. It probably helps if you read that post first.In Friday's post I outlined the state of play regarding UCB's important Vimpat patent. Disputes about that patent have been background for the stock for some time. When I went to visit UCB in Belgium (1 December 2015) the IR officers were straightforward about this. Third party patent challenges were the bear story on the stock. But UCB has since then touted victories in their patent disputes and regularly touted extensions of the Vimpat franchise.On 14 August 2016 UCB released a press release titled U.S. District Court confirms validity of patent for UCB's Vimpat®. That press release detailed a key victory against one of two third-party challengers of the patent. The stock went up sharply. UCB has made many press releases detailing just how important the Vimpat franchise is to them. When the CEO (Jean-Christophe Tellier) was appointed the press release stated: "Jean-Christophe Tellier joined the company in 2011 and was instrumental in establishing the company’s current strategy; he has played a key role in driving the growth of UCB’s three core medicines, Cimzia®, Vimpat® and Neupro®."UCB has been active in touting Vimpat both in the EU and the US as a monotherapy for epilepsy. (See here and here.)UCB has been extremely active extending labels for Vimpat in Japan. (See here for an example.)Indeed extensions of the Vimpat franchise have been important in UCB's growth strategy.So it was deeply surprising to us when UCB neglected to tell the market that US Patent Office had reviewed the patent (an ex-parte review) and had decided to withdraw the patent entirely. [You can find the letter that the Patent Office sent here.]This is an unusual move. Since the ex parte examination system was introduced (35 years ago) about 13,500 ex parte requests for examination has been made just over a thousand of them have had all claims rejected. You can find statistics here. Rejected here is a term of art. A claim is "objected" for all sorts of formal reasons like the claims not being properly grouped. A "rejection" is a determination that the claim is not patentable - and is appellable to the Patent Trial and Appeal Board (a court) and then to the court system. This is altogether a different type of threat to UCB. Past patent disputes have been with other companies wanting to release a generic - and thus far UCB has either had the case thrown out or got a significant delay. These are standard commercial disputes with commercial parties. And in every one of these disputes the court has worked on the assumption that UCB has a valid patent and the question is whether the other party is infringing on this patent. This dispute is with the US Government. The US Government has reviewed past decisions and decided that Vimpat is simply non-patentable. That is the US Government has determined that UCB does not own a valid patent. Sure UCB has two months to try and convince a (well informed) patent examiner otherwise - but their chances of this are low. The patent examiner will be experienced in this area and it is not as if the bureaucrat was uninformed that this was a controversial and important case.After the two months has elapsed UCB could appeal to the Patent Trial and Appeal Board. However the standard here is the de-novo patent standard. The situation is as if Vimpat had its original patent comprehensively rejected and it has to appeal to a court against the scientist/reviewers at the Patent Office. The courts are usually pretty deferential to the examiners at the Patent Office on the basis that they have the disinterested expertise to assess patents. In this case Johnny Railey was the examiner and he is amongst the most experienced biotech patent examiners in the US. You can find his linked in CV here. You can find a very extensive list of patents in which he was the examiner here. Appeals of this kind almost always fail. As Johnny Railey is amongst the most experienced patent examiners the chance of an appeal succeeding is even lower.For practical purposes the Vimpat patent is almost certainly dead - and UCB's much ballyhooed growth strategy will die with it.I am surprised at the lack of a management press release.Disputes with the US GovernmentUCB has press released interim victories in District Court against commercial claimants on the Vimpat patent.Their IR officers have been willing to give up-to-date reports of the (mostly) favourable commercial disputes they have.But there is not a word here that their (new) dispute is with the US Government and the default position from here (statistically likely to be upheld) is that they will lose their patent in its entirety.Not disclosing a business-critical dispute with the US Government is strange.Whatever: shareholders should ask themselves how other European companies have prevailed in dispute with the US Government.John
UCB is a Belgium-based biopharmaceutical and specialty chemical company that specialises in two therapeutic areas: diseases of the central nervous system and immunology. The main central nervous system speciality is epilepsy and the main drug in this area is Vimpat. (UCB revenue mostly comes from four drugs of which Vimpat is one.)We went to visit UCB once, a cold and wet wintery day where we got modestly lost in Belgium.The investor relations people were straightforward. We were new to the story and our notes state clearly that generic challenges to the Vimpat patent were the main bear story for the stock. Our notes also talk about Keppra - another epilepsy drug. When it went off patent revenues dropped substantially. Keppra was an famous "patent cliff" drug.The risk to Vimpat has been reflected in the press too. Fierce Pharma - an industry rag - reports that August 15 this year was the best day for UCB in years as a Delaware District Court had rejected challenges to the Vimpat patent. Notwithstanding this, Fierce Pharma noted that the patent still faced challenges. To quote:UCB isn’t totally out of the woods, though. In late May, New York-based generics maker Argentum Pharmaceuticals won an inter partes review of Vimpat’s patent protection by the U.S. Patent & Trademark Office (PTO)’s Patent Trial & Appeal Board (PTAB). And that decision may not be handed down until next May. Still, court’s decision is a “long-awaited sentiment boost” for UCB, whose shares had fallen by about 17% so far this year, Citigroup analysts wrote in a Monday note seen by Bloomberg. Despite the lingering risk of patent invalidation, they wrote, “we expect market confidence to improve.”As noted Argentum Pharmaceuticals won an inter-parties review of Vimpat's patent. Argentum's press release however noted an even more aggressive request. To quote:Argentum also filed an ex parte reexamination request against this same patent that raises additional grounds of unpatentability than those in the IPR. A decision by the PTO on Argentum's reexamination request is due no later than July 29, 2016.This is mentioned as afterthought in the press release because it is a really aggressive claim. Argentum asked the Patent Office itself to review the patent it previously granted and presumably throw out the original patent.Given the afterthought nature of that request I suspect even Argentum will be surprised that the ex-parte review rejected all thirteen claims of the Vimpat patent.In other words the Patent Office has thrown out the patent.This is all in a letter dated 5 December 2016 (that is just a few days ago). You can find that letter here. And according to that letter UCB has only two months to dispute the total rejection of the patent by the patent office.This rejection will of course be followed by Argentum and Mylan (and probably other companies) commencing distribution of a generic for Vimpat. Mylan were behind the above-mentioned court challenge.--It is - given the significance of this to the business - perhaps a little unusual that UCB has made no press release.--Is this the beginning of a new, more aggressive patent office?The political pressure in the US to do something to reduce drug prices is large. In the past election this was one area of near universal agreement.I am wondering whether we are going to see this sort of action by the Patent Office more widely.If the trend is more widespread it could be bad news for pharma investors generally.John
Amgen, Inc. (AMGN) and partner UCB S.A. (UCBJF) announced results from the pivotal phase III BRIDGE study which showed that its pipeline candidate, romosozumab, significantly increases bone mineral density in men with osteoporosis.
BELGIAN drugmaker UCB’s efforts to improve quality of life for people with severe diseases have benefited millions of Chinese patients in the past two decades. The Brussels-based multinational biopharmaceutical
Dr. Reddy's Laboratories Ltd. (RDY) reported second-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 27 cents, down 57.1% year over year.
Consumer products company Helen of Troy Limited (HELE) is all set to boost its presence in the health and wellness business.
Those are the topics covered tomorrow (Friday, 10/14) at the 5th annual West Coast Workshop in International Finance 2016, taking place at Santa Clara University. As usual, these look like a set of fascinating papers, and a must-see for those interested in international finance/open economy macro (A post discussing last year’s conference proceedings is here). […]
Although Amgen (AMGN) gained FDA approval for its biosimilar of Humira, Kyprolis data disappointed.
Amgen Inc. (AMGN), along with its partner UCB S.A. (UCBJF), a global biopharmaceutical company, announced that the FDA has accepted their Biologics License Application (BLA) for romosozumab for the treatment of osteoporosis.
Amgen, Inc.'s (AMGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for its pipeline secondary hyperparathyroidism (SHPT) candidate Parsabiv (etelcalcetide).
Matt Walsh is at this point best known for his exceptional character work in sitcoms and movies like Veep, Reno 911!, Old School, and Ghostbusters. But to many in the comedy community, Walsh is legendary for his work as an improviser first in Chicago, and then in New York and Los Angeles as one of the four co-founders of the Upright Citizens Brigade Theater.
Every woman working in comedy knows about them. They’re usually hidden from public view, but have hundreds of members. They’re most common in Los Angeles and New York, and sometimes are split between improv, stand up and sketch performers. And inside, the discussion can range from job postings and asking for advice about boyfriends, to outing men accused of sexually assaulting multiple women. In the past few years, private Facebook groups for female comedians have sprouted up throughout the country, though typically focused in major cities with active comedy scenes. The groups, sometimes completely secret and unsearchable unless you’re invited in, often started as a refuge for women working the male-dominated comedy business. “Female comics need an outlet to deal with things,” said Kelly Anneken, a comedian based in San Francisco, who’s an active member of a group called Mermaid Pants. “The secret groups are how we’ve chosen to deal with it because there’s no HR department in comedy.” These groups largely go unnoticed by the broader public and rarely become the topic of conversation in the comedy community until something happens ― like earlier this month when a member of one group shared a message that comic Aaron Glaser of committing sexual assault. The word spread quickly outside of the group that Glaser was banned from the Upright Citizens Brigade theaters over complaints from women, though he denied the allegations. After the claims came out against Glaser, The Huffington Post spoke with nearly three dozen women working in comedy. Many shared a similar sense of an uphill climb simply to exist in the comedy community as a woman. Every industry has problems with sexism and harassment, they said, but comedy is a tough business where everyone’s working off their personal reputation as a freelancer to find a gig in the next alcohol-serving establishment. The secret groups are how we’ve chosen to deal with it because there’s no HR department in comedy. Kelly Anneken, who works in comedy programming and performs in San Francisco Women have long had to deal with arguments about whether it’s even possible for them to be funny. Now there are plenty of signs of success for women in the business, from Amy Schumer becoming the first female comedian to headline at Madison Square Garden, to the many talented women starring in Comedy Central series like “Broad City,” “Not Safe With Nikki Glaser” and “Another Period.” But no women have their own late night talk shows, and in 2015’s season of “The Half Hour,” Comedy Central booked just three women compared to 11 men, and that was the highest ratio yet of women in five seasons of the stand-up special series. “There’s progress, but it’s not the systemic change,” said Anneken, who was the former head of programming for Pandora comedy. “It feels like a Band-aid at this point.” Aside from the fact that most comics booked at venues are men, several female comics said it’s far from unusual for a guy with clout in the local comedy scene to offer them “really nice spots” in lieu of “favors.” “There’s always going to be bad apples in any profession or scene,” said Dean Masello, a comic based in New York, “but how many women I’ve heard who’ve been approached after the show or guys come to them during the show, or been implicitly offered stage time for sexual favors ... I’m surprised how much misogyny is in the stand-up world in this day and age.” Masello is a former lawyer from Ohio who spent several years representing victims of domestic violence. He’s witnessed some of the harassment his female colleagues endure at shows, only to have them turn around and tell him, “This is nothing, this is average.” Given that, Masello said, it makes sense that women would want to arrange private Facebook groups or all-female lineups for comedy shows. Yet there are men who consistently push back against those. “When we started the group, some guys were taken aback ― they figured we’re talking about them all day,” explained Katie Compa, who co-moderated a private Facebook group, NYC Lady Comics, along with Selena Coppock. “That’s only occasionally true.” Another common complaint from female comics is that male comics hit on them and then proceed to gaslight them about it. For example, in May, screenshots were posted online showing comedian Mike Faverman lashing out at a woman who gently declined his invitation to dinner, with him saying, “I know you’re not out of my league in the least, please stop acting as if I wouldn’t have a chance,” and advising her to not be “an angry c**t.” In other words, Faverman said he had just been joking and the woman was crazy for thinking he had actually been hitting on her. Faverman apologized after screenshots of his offensive messages circulated online, but days later went back to suggesting on Twitter that women sometimes deserved the harassment they received. Anytime something happens to a woman does anyone ever wonder why it happened or do they just assume it had nothing to do with what she did??— Mike Faverman (@mikefaverman) May 27, 2016 HuffPost obtained additional screenshots of offensive messages Faverman sent to women, including him telling a woman there’s no way a man would date her unless she provided oral sex to him regularly, asking a woman when he could pick her up from the pound, and saying a woman was exposing her body because no one cares about what she has to say, then asking her to get coffee. Several women characterized this attitude from male comedians as, “I want to have sex with you, unless you don’t want to, in which case I’m joking.” “I think there’s a list in every women-only group of creepy guys to avoid,” Compa said. Compa’s group for women in New York City started as an outgrowth of occasional get-togethers for female comics. But when they witnessed male comics express sexist comments on Facebook, the private group for women became solace. For example, Compa remembers when UCB started hosting an open mic just for women, called “Open Michelle,” some guys in the comedy scene voiced complaints like, “That’s not the real world,” or “Performing at an open mic that’s all women is not going to make you a better comic.” When a lineup is made entirely of women, “it becomes a thing,” said Claire Armstrong, who books comedy shows. “If it’s all men on the bill, it’s just a comedy show. If it’s a lineup with all women on it, people start calling it a women’s show.” I think there’s a list in every women-only group of creepy guys to avoid." Katie Compa, New York-based comedian Kim Dinaro runs a regular all-women show in Brooklyn called Left Breast Comedy Hour. She’s heard a few men complain about how feminist the show is, like one who insisted “if he went up there and talked about how women were awful, it wouldn’t be tolerated.” It’s an argument akin to saying “all lives matter,” Dinaro said; it’s not helpful. What was helpful for Dinaro, she said, was a private group like NYC Lady Comics, where she could ask for advice on how to deal with that criticism and “navigate this difficult world of being the minority in comedy.” These groups helped start to turn the tide in the past few years, Compa argued, because more women’s stories can be heard and validated. They became digital “safe spaces” for women in the industry to talk through how to deal with personal issues like assault or harassment, as well as ask basic questions like whether it’s worth joining the Screen Actors Guild. Yet nothing online is truly private. The same weekend the allegations against Glaser surfaced on Facebook, NYC Lady Comics shut down after someone shared a screenshot of comments made within the forum, seemingly in real time, with a comedian who has a large following online. It wasn’t the first time someone leaked screenshots in the five years that group was active, so the administrators decided to close it down entirely. However, even if one group shuts down, Anneken insists that these private forums aren’t going away entirely. “They exist because women can’t depend on male allies to back them up,” Anneken said. “The reason there are leaks are so that women can curry favor with men who essentially don’t want these groups to exist. If men in the comedy community and the world at large aren’t willing to engage and hold each other accountable, we have no choice than to create and maintain these underground systems to keep ourselves safe.” ______ Tyler Kingkade is a national reporter who covers sexual violence. You can reach him at [email protected], or find him on Twitter: @tylerkingkade. Related Coverage: Comedians Who Are Sexually Assaulted Must Decide: ‘Career Above My Dignity’? Music Festivals Have A Glaring Woman Problem. Here’s Why. Trying To Understand Consent? Ask The LGBTQ And Kink Communities Secret Feminist Group Is Taking On The Judge In Brock Turner Case And People Ask Why Rape Victims Don’t Report To Police -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Cathy hesitated for months to tell anyone about the fellow comedian in Los Angeles who she said sexually assaulted her. The comedy community is small, and Cathy feared backlash. But one night in November 2015, after months of therapy and at the urging of other female comics, Cathy felt confident enough to post her account of the assault, using the man’s name, in a private, all-female Facebook group for comedians. Within two minutes, someone had provided a screenshot to the guy, Cathy said. The man started calling women who were commenting on the post so he could tell them Cathy was a liar. “I felt totally alienated,” said Cathy, who asked that this article not use her real name. “In the brief moments of support it was like, ‘Oh, there’s hope, people got my back.’ But everything I thought was going to happen happened.” She deleted her post within half an hour of putting it up. The comedy world was abuzz last week over sexual assault allegations against the New York-based comedian Aaron Glaser. As in Cathy’s case, the accusations were first aired in a private, all-female Facebook group for local comedians. But the allegations against Glaser weren’t posted by one of his accusers. Rather, an administrator of the group posted the allegations on behalf of Glaser’s accusers ― along with news that Glaser had been banned from the beloved Upright Citizens Brigade theater, where many well-known actors got their start. In more and more cities across the U.S., there are private Facebook groups for female comics ― online resources that help women find work and navigate sexism in a competitive, male-dominated industry. But they’re also not infrequently used to identify men who sexually harassed or assaulted women in the decentralized profession, where virtually everyone is a freelancer. It’s an imperfect solution in a society where sexual assault reports rarely result in criminal charges, let alone convictions. Complicating matters is the fact that in the comedy world, everyone’s reputation is also their career. The accusations against Glaser were raised in a secret, unsearchable Facebook group, one that’s been used in the past to identify serial harassers or assaulters. There have been times when multiple women in the group compared stories about a single man and then went together to UCB or to the police. But by the time the group of women who accused Glaser went to the Facebook group, they’d already told UCB, and could share an email confirming Glaser’s ban. At least four women reported sexual assault allegations against Glaser to UCB, sources close to the women told The Huffington Post. Glaser posted a statement on Facebook that he later deleted, insisting that he was innocent and that he didn’t know what the specific allegations against him were. “The woman who contacted us said she wanted to get the word out so if there were other victims, they could come forward,” said Gina Ippolito, an admin of the secret Facebook group. “She does not want to put her name out there because she has seen how other women have been treated in the past when they talk about their experience being sexually assaulted in the community.” "The status quo is to not believe women, and that's a thing that's been going on for eternity." Erika Heidewald, a Los Angeles-based UCB performer The allegations sparked a heated debate online. Most of the people talking about the blowup seemed to support the accusers, according to several comedians who spoke to HuffPost. But some people wondered whether Glaser had been railroaded. Most notably, comedian Kurt Metzger posted a torrent of comments on Facebook and Twitter criticizing the whole idea of reporting rape to a comedy venue rather than to police. “Saturday Night Live” comic Michael Che made a similar remark when asked if he was aware of the allegations against Glaser. (At least one of the alleged victims did report to police, sources said.) Metzger later elaborated on the “Race Wars” podcast that he was upset by this case because he didn’t know who the accusers were or what they were specifically alleging, and because Glaser said in one Facebook post that he was never given a chance to defend himself to UCB. It was a dangerous precedent, Metzger insisted. “There is all this blowback because the comedy community is reflexively believing women, but really, that’s a very new thing,” said Erika Heidewald, a UCB performer based in Los Angeles. “The status quo is to not believe women, and that’s a thing that’s been going on for eternity.” Cathy, for her part, understands exactly why the women bringing allegations against Glaser wouldn’t want everyone to know their names. “Friendships and alliances exist ― a lot of the time getting booked has less to do with your ability and more [with] who you’re friends with,” she explained. “If you don’t have as much pull as the person who assaulted you, which is horrifying, then you’re definitely not going to put your name out there.” This sort of backlash is what prevented Cindy, who performs improv in a city in New England, from making a report about a fellow comic who she says assaulted her one night when she was still new to the scene. Cindy still sees the man around venues, and he usually tries to hug her, “but I don’t let him,” she said. “In my theater, all of the people in charge are men. Why would I feel comfortable reporting to a guy that’s higher up at the theater?” said Cindy, who also asked that her real name not be used. “Especially since they know the person and you’re just getting started out.” "It’s like I’m going to put my career above my dignity." Cathy, a comic based in Los Angeles Sexual assault victims are often given anonymity in news articles to protect their privacy. Comedians, like other entertainers, have additional reasons to want to keep their names out of stories like this: They could face backlash from their colleagues, or lose out on work because they’ve become associated with controversy. There’s also a worry that their experience with sexual assault could come to define them. As Heidewald put it, “Former Rape Victim Gets Netflix Special” is not a headline a comic wants attached to their success. “It’s like I’m going to put my career above my dignity, almost,” Cathy said. “That’s what you have to do. Am I going to be a part of this community or am I going to be a leper?” For Glaser to get banned from a major comedy venue wasn’t unusual in and of itself, but this case was more high-profile than most. Several comics pointed out that people have been banned from venues over physical or verbal fights, or simply for having a negative attitude. One performer mentioned a comic who’d gotten banned from UCB for a sexual misconduct issue. This person, though, was able to save face and portray it as a voluntary departure, since the allegations against him never became public. UCB won’t comment on the Glaser case. The group sent HuffPost the same statement it sent every other outlet, mentioning that it encourages people to report harassment concerns to the UCB staff. Several workplace law experts told HuffPost that UCB likely wants to avoid opening itself up to a defamation lawsuit from Glaser. The industry is dealing with this in other cities. In Minneapolis, comics in a group called Fair Play MN have worked with venues to establish systems so people can report anonymously to the theaters if a fellow performer has harassed or assaulted them. Hannah Wydeven, one of Fair Play’s co-founders, said that when it results in a male comic being banned, it’s often done quietly for the victim’s sake. “For us, for Fair Play, the number one priority we have is to keep the victim or reporting person safe,” Wydeven said. “I don’t give a shit what happens to the person who gets reported. If their name is tarnished or if they slip out quietly, then that’s just what happens.” Fair Play has established a process for dealing with accusations of assault or harassment. The group collects testimony from women and compiles it into a report, which it sends to theaters. Each venue can then decide, based on that information, whether it wants to ban the accused performer. Once that’s done, “we notify the community of women that this person has been causing problems,” Wydeven said. The group adopted this approach after an earlier incident where they jumped straight to calling out an alleged harasser, which led to backlash. “I’ve definitely learned, as a woman who’s trying to navigate the world of building equity,” Wydeven said, “you have to prepare for the worst because nobody is going to give you any fucking slack.” The downside of discretion, though, is that when things are handled quietly and without any kind of formal statement, people are left to gossip and speculate about what really happened. “Everyone’s trying to figure out the information, and Reddit becomes the ultimate authority,” the UCB performer said. “And that’s not right.” After word got out about Glaser’s ban, several other venues in New York said they would also ban him. The fact that there’s been any action at all, several female comics told HuffPost, is progress. “That is the difference to me,” said Laura High, a comic in New York. “That’s a milestone ― the fact just that we are talking about it.” Need help? Visit RAINN’s National Sexual Assault Online Hotline or the National Sexual Violence Resource Center’s website. ______ Tyler Kingkade is a national reporter who covers sexual violence. You can reach him at [email protected], or find him on Twitter: @tylerkingkade. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
UCB (UCBJF) announced that the Delaware District Court has confirmed the validity of the company's patent (U.S. patent RE38,551) for its epilepsy drug, Vimpat.
Фондовые индексы Западной Европы слабо изменились по итогам торгов в понедельник, при этом германский индекс DAX полностью восстановился после снижения с начала года.
UCB (UCBJF) reported results for the first half of 2016.
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene